DailyRounds

Market position

DailyRounds operates in India's healthtech and medical edtech segment. Company milestones claim that by 2017 one in two doctors in India used DailyRounds (450,000 doctors) and that by 2018 two in three medical students used Marrow (300,000 students); in 2023 it reported a network of over 300,000 doctors, about 200,000 Marrow users and roughly 400 new doctors joining daily. Unlike several Indian edtech peers reporting large losses in FY22, the company reported a profit of INR 198.09 Cr for FY22.

The company combines clinical-community and reference content with exam preparation, spanning digital self-study (Marrow), classroom and live coaching (DBMCI One), institutional assessment tooling (Creator+), a drug reference database (India Drug Index) and a doctor benefits network (GliaCircle). Marrow's positioning emphasises clinical and concept-based learning with faculty-recorded lectures and a large question bank, and DBMCI is described as the first centre in India to provide medical PG entrance training. Backing by M3, Inc. connects the company to a global physician network.

Technology

Mobile and web applications for clinical case publishing, recorded video lectures, question banks and test series; an automated question-paper generation tool drawing on a curated MCQ bank; and a structured drug information database. The company has used AWS for large-scale file migration and cost optimisation.

Go-to-market

Products are distributed directly to medical students and doctors through mobile and web applications and subscription plans, supplemented by in-person and live classroom coaching under the DBMCI brand and an institutional sales motion for Creator+ aimed at medical colleges and faculty. Content marketing through a blog covering medical education, clinical topics and Indian health policy supports user acquisition, and the company reported roughly 46,000 monthly website visits.

Doctors and clinicians in India, MBBS students and postgraduate medical aspirants preparing for NEET PG, NEET SS, INI-CET and FMGE, and medical colleges, institutes and faculty that need assessment tools.

Geography

Headquartered in Bengaluru, Karnataka, India, with products aimed primarily at Indian medical students and doctors, including pan-India test series and face-to-face classes. Through parent M3, Inc., the group operates across nine countries: the USA, UK, Germany, France, Spain, India, China, Japan and South Korea.

History

The company traces its origins to a 2013 email group formed to solve clinical cases. In 2014 it joined accelerator programmes run by GSF and Microsoft and passed 100,000 users; it was also part of the Microsoft Ventures Summer 2015 batch. RadiologyRounds launched in 2015 alongside a partnership with GE, followed by India Drug Index and Anaesthesia Rounds in 2016 and Marrow in 2017. Courses, CMEs and programmes were added in 2021. In April 2019, M3 India, the Indian arm of Tokyo-based M3, Inc., acquired a majority stake in parent company Neuroglia Health Private Limited. In 2023 the company acquired Dr. Bhatia Medical Coaching Institute Pvt Ltd (DBMCI) and launched Creator+, and cofounder Deepu Sebin exited all roles at DailyRounds and Marrow, with Vineet Bagri promoted from business head to CEO. GliaCircle launched in 2025.

Risks & controversies

Publicly reported figures for the company differ across sources: founding year is given as both 2014 and 2015, total disclosed funding as $500K or $1.7M, headcount as 355, 519 or 151-250, and FY25 revenue as ₹696.3 Cr or ₹773.1 Cr within the same data provider. Leadership turnover included the 2023 exit of cofounder and long-time CEO Deepu Sebin.